Seeking Alpha

OSIRIS THERAPEUTICS (OSIR)

()

News & PR
Market Currents

Buzz
Twitter: OSIR

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Graft-Versus-Host Disease: Failures and Future Opportunities

Dec 10 • Michael Becker • Comment!
Expiration Trade Behind Osiris Activity

Nov 20 • optionMONSTER • Comment!
Tuesday Options Recap

Nov 3 • Frederic Ruffy • Comment!
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers

Sep 20 • Justin M. Hall • 3 Comments
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11 • Justin M. Hall • 23 Comments
Closing Update: Stocks String Together 3 Straight Wins, Commodities Gain

Sep 8 • Midnight Trader • 4 Comments
Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 2

Aug 27 • M. E. Garza • 3 Comments
Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 1

Aug 27 • M. E. Garza • 1 Comment
'Lucky 13 Portfolio': Fuel Systems and Three Cancer Drug Makers

Aug 25 • Justin M. Hall • 5 Comments
Monday Options Recap

Aug 24 • Frederic Ruffy • Comment!
Ariad Pharmaceuticals: Advancing in Front of Phase 3 Interim Results

Jul 29 • Justin M. Hall • 8 Comments
Spectrum Pharmaceuticals: Outlook Remains Very Promising

Jul 27 • Justin M. Hall • 20 Comments
Adult Stem Cell Drugs and Therapies Are the Next Big Market

Jun 18 • M. E. Garza • 10 Comments
Stem Cell Index Surges in Past Week

May 11 • Mike Havrilla • 3 Comments
Optimistic on Osiris Therapeutics

May 8 • Zacks.com • Comment!
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson

Apr 23 • Mike Havrilla • 1 Comment
Banking on NeoStem

Apr 12 • Mike Havrilla • 4 Comments
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly

Apr 2 • Mark Cifra • 5 Comments
8 'Bathwater Babies' and 20 'Dogs with Fleas' Stocks for the Week

Mar 30 • J Clinton Hill • Comment!
FDA and Clinical Trial Updates: Osiris Sees Flaw in Crohn's Disease Trial

Mar 29 • Mike Havrilla • 2 Comments
Osiris Hits a Speedbump in Crohn's Program

Mar 27 • Zacks.com • 2 Comments
With Funding Ban Lifted, Stem Cell Index Soars

Mar 10 • Mike Havrilla • Comment!
12 Stem Cell Stocks - Updated

Mar 9 • Stockerblog • 8 Comments
Know Your Options When Investing in Biotech Stocks

Mar 2 • Zacks.com • 5 Comments
Osiris Therapeutics Enters a New Age of Pharma Risk and Profit Share

Feb 8 • Dusan Bogunovic • 1 Comment
Little Rays of Sunshine in the Markets

Feb 6 • Richard Shaw • 3 Comments
Trading the Trials and FDA Decision Calendar

Jan 26 • Mike Havrilla • 1 Comment
Stem Cell Research Stocks Soar as Obama Takes Office

Jan 25 • Mike Havrilla • 5 Comments
20 Emerging Healthcare Stocks to Watch in '09

Jan 11 • Mike Havrilla • 4 Comments
9 Possible Pharma Deals for 2009

Jan 8 • Zacks.com • 7 Comments
Stem Cell and Regenerative Medicine Stocks Surge in December

Dec 20, 2008 • Mike Havrilla • 7 Comments
Healthcare: Investing Trends for 2009

Dec 19, 2008 • Mike Havrilla • 3 Comments
Cytori Therapeutics and Cypress Bio: Two Buys Based on Positive Trial Results

Dec 9, 2008 • Mike Havrilla • Comment!
ETF Ideas Poised to Benefit from Pending Healthcare Reform

Dec 8, 2008 • Mike Havrilla • 1 Comment
New Emerging Biotech and Pharma Company Index

Nov 23, 2008 • Mike Havrilla • 3 Comments
Regenerative Medicine: Big Pharma's Next Frontier

Nov 19, 2008 • Mike Havrilla • 2 Comments
ETFI Global Healthcare Sector PerfomIdex

Nov 9, 2008 • Mike Havrilla • 1 Comment
Genzyme and Osiris Get Together on Stem Cells

Nov 5, 2008 • Mike Huckman • Comment!
Cosmetic and Reconstructive Medicine ETF Outpaces Healthcare Sector

Nov 2, 2008 • Mike Havrilla • Comment!
Three Biotechs Hitting New 52-Week Highs

Sep 24, 2008 • John C. Lee • 5 Comments
10 Biotechs in Stem Cells that Could Profit Under the Democrats

Jun 1, 2008 • Ketan Desai • 16 Comments

OSIRIS THERAPEUTICS (OSIR)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers